Topoisomerase IIa (topo IIa) is a major target of antitumor treatments. In an eort to determine why this protein might be a better target in tumor cells than in normal cells, we attempted to determine if the altered proliferative signaling in a tumor cell might eect the levels of expression of the topo IIa gene. In support of this idea, it was found that topo IIa was elevated following microinjection of oncogenic Ras protein.
Introduction
Cellular Ras plays a central role in the control of proliferative signaling, explaining in part why up to 30% of all naturally occuring tumors contain activated ras mutations (Bos, 1989) . Under normal circumstances the action of Ras and other members of the Ras pathway are strictly regulated during the cell cycle and in dierent growth conditions. In a tumor cell, where mutant signaling proteins such as Ras generate a continuous proliferative signal, it is possible that downstream protein targets of that signal transduction pathway might be expressed abnormally. Among the molecules of interest when considering dierences between normal and tumor cells is topoisomerase IIa (topo IIa). This molecule plays a critical role in the maintanence of DNA structure throughout the cell cycle, and is a major target of a number of antitumor drugs (Chen and Liu, 1994; Wang, 1996) . It is possible, therefore, that there exists a connection between the continuous signaling by Ras and the expression of topo IIa, which might be of importance in understanding the role of topo IIa as a target for selective tumor killing.
A major function of Ras in normal cells is to receive the signal from tyrosine kinases, which are normally activated upon mitogen treatment, and transfer this signal to a cascade of serine or dual speci®c kinases (Hunter, 1997) . The signal transfer between tyrosine kinases and Ras involves a series of molecular interactions which brings Ras together with its exchange factor, resulting in replacement of bound GDP with GTP and activation (Boguski and McCormick, 1993) . Once activated, the Ras protein binds to the cellular Raf protein, resulting in its activation. Active Raf is the ®rst in a cascade of other kinases, including MEK, which phorphorylates and activates the mitogen activated protein kinase ERK (Bos, 1989; Lange-Carter et al., 1993) . Activated ERK is then able to phosphorylate and regulate the activities of several transcriptional factors, including Jun, Fos, TCF/Elk-1 and other members of the ETS family, the cAMP responsive element binding protein and serum response factor (Hunter, 1997) .
While the Ras/Raf/MEK/ERK cascade plays a central role in proliferative signaling, there is also evidence that Ras activity can lead to the activation of MEK kinase (MEKK) (Minden et al., 1994; Russel et al., 1995; Westwick et al., 1994) . MEKK is a critical component of the stress kinase cascade including SEK and stress-associated protein kinase (SAPK, also called Jun amino-terminal kinase JNK) Sanchez et al., 1994; . This cascade is activated by various cytokines and stressful conditions including UV irradiation, TNF-a, osmotic shock and protein synthesis inhibitors, and has been reported to play a role in apoptosis (Chen et al., 1996; Xia et al., 1995) . Several small GTP-proteins are able to trigger this cascade, including Rac1 and Cdc42 Coso et al., 1995) . As with ERK, SAPK is known to phosphorylate and activate transcriptional factors including c-jun. The AP-1 transcription factor is composed of c-jun along with the ERK target c-fos, and functions as an important component of the signaling pathway leading to cellular proliferation or dierentiation (Hunter, 1997) . The important role of the SAPK pathway in Ras mitogenic signaling has been suggested by the observation that inhibition of SAPK activation suppresses Ras oncogenic activity (Clark et al., 1997) ; and Ras can only poorly transform c-Jun null cells (Johnson et al., 1996) . It is likely, therefore, that this stress pathway may also be involved in transduction of Ras signaling to down-stream target genes.
Among the proteins required for cell division are the DNA topoisomerases, which function to resolve topological constraints in DNA (Chen and Liu, 1994; Wang, 1996; Berger et al., 1996) . Of these, topoisomerase IIa is unique in that it is regulated during the cell cycle, is involved in cell proliferation and differentiation, and is increased in many tumor tissues (Woessner et al., 1990 (Woessner et al., , 1991 Nelson et al., 1987; Isaacs et al., 1996; Hsiang, 1988) . The levels of topo IIa are low in quiescent or dierentiated cells, but increase as cells enter later stages of the cell cycle, particularly G2 and mitosis (Watt and Hickson, 1994) . Since catenated DNA must be resolved prior to separation of chromatids during mitosis, topo IIa is a critical molecule during mitosis (Bhat et al., 1996; Downes et al., 1994; Holm et al., 1985) . Its intimate association with DNA, as well as its frequently increased expression in tumor cells, makes it an excellent target for tumor-speci®c cytotoxic treatments. Indeed, topo II inhibitors have become a major class of anticancer drugs in the clinic (Chen and Liu, 1994) . Despite the critcal role of topo IIa in cell proliferation, however, little is known about the signaling mechanisms for its regulation. Recent studies from two laboratories showed that p53 can inhibit Topo IIa expression (Sandri et al., 1996; Wang et al., 1997) . It is reasonable to predict that the regulation of this gene might be critical in understanding the ability of its inhibitors to selectively kill tumor cells. We, therefore, tested the possibility that oncogenic ras, a common alteration in tumor cells, might directly in¯uence topo IIa expression. Care was taken to ensure that the eects of Ras upon topo IIa expression were not confused with the eects of Ras upon cell cycle progression, which would then indirectly lead to elevation of topo IIa levels. Our results established a link between Ras signaling and topo IIa expression. The information gained might be of value in understanding the alterations present in tumor cells which sensitize them to killing by topo II inhibitors.
Results

Increase of topo IIa protein by oncogenic Ras
To establish the connection between oncogenic Ras and topoisomerase IIa (topo IIa), topo IIa levels were analysed in normal NIH3T3 cells and these cells transformed by oncogenic ras. The increase of topo IIa protein and mRNA upon transformation by Ras have been previously reported in NIH3T3 cells (Woessner et al., 1990) . We found topo IIa protein to be increased 1.5-fold in ras transformed cells compared to untransformed cells in Western blot analyses (P50.05, data not shown). For the studies to follow, however, it was necessary to be able to determine the topo IIa levels in individual cells. For this purpose topo IIa was stained in an asynchronously proliferating culture of NIH3T3 cells with a speci®c,¯uorescence antibody. The stained culture was then photographed with a sensitive CCD camera and the levels of topo IIa-associated¯uorescence in the nuclei of individual cells was determined from the resulting image using image analysis software. When the topo IIa signals from 200 ± 300 cells were measured, the topo IIa signals were signi®cantly higher (1.45-fold) in ras-transformed NIH3T3 cells (RAS) compared to the normal cells (3T3) (P50.01, Figure 1a) . Thus, the results obtained by Western blotting and immunostaining, were consistent with each other and with previously published results (Woessner et al., 1990) .
It was critical to establish that the increase in topo IIa protein levels was a direct result of the activity of oncogenic Ras, rather than a consequence of the general transformed phenotype. Therefore, oncogenic Ras protein (1 mg/ml; Ras Leu 61) was microinjected into untransformed, quiescent NIH3T3. Rat IgG was coinjected with the Ras protein to allow positive identi®cation of the injected cells. As a control, rat IgG was injected alone into separate plates. At 20 ± 24 h after injection cells were ®xed and doublestained against topo IIa and Rat IgG. Topo IIa levels in the uninjected, serum-starved NIH3T3 cells were low (Figures 1b and  2a) , consistent with previous observations (Hsiang, 1988; Woessner et al., 1990) . However, the oncogenic Rasinjected cells responded by producing high levels of topo IIa (Figure 2a , top left panel), while none of the control injected cells was positive for topo IIa staining ( Figure   Figure 1 Regulation of topo IIa expression by Ras activity. (a) The topo IIa levels in NIH3T3 cells, and these cells transformed by ras, was determined by quantitative analysis of the¯uorescent staining of individual cells. These results are compared with the reduction of this level following injection of anti-ras antibody. The ras transformed NIH3T3 cells received injection of neutralizing anti-ras antibody. After 24 h these cells were ®xed and stained for both topo IIa and for the injected immunoglobulin (to identify injected cells), as well as for DNA (with DAPI). The total topo IIa-associated¯uorescence in the nuclear region of injected cells (RAS+259/MI) was determined and compared to similar analyses for neighboring uninjected cells (RAS), and for uninjected NIH3T3 cells on a separate plate (3T3 (Figure 1b) . Furthermore, the cells were morphologically transformed by the injected Ras as indicated by a more refractile, spindle shape appearance in phase-contrast optics (Figure 2a , bottom left panel), and the overall shape of the cells (indicated by staining for the injected immunoglobulin; Figure 2a , middle panels). These results remove any potential complication of clonal variations associated with the results from transfected clones described above, and demonstrate directly the extent of topo IIa induction by Ras activity.
Decrease of topo IIa following microinjection of an antiRas antibody
The studies above indicate that Ras is able to directly stimulate topo IIa levels in NIH3T3 cells. Microinjection of a neutralizing antibody against Ras was next performed to determine if the high topo IIa levels in ras-transformed cells required the continued presence of Ras (Smith et al., 1986) . For this determination, a neutralizing anti-Ras antibody was microinjected into ras-transformed NIH3T3 cells. At 24 h following the injection all anti-Ras-injected cells had reduced levels of topo IIa (Figure 2b Figure  1a ). The ability of anti-Ras to reduce topo IIa levels in ras-transformed cells to even lower levels than seen in untransformed NIH3T3 cells most likely results from the inhibition of endogenous Ras activity in these cells (Smith et al., 1986; Mulcahy et al., 1985) . Thus, it is apparent that Ras activity is not only sucient but also necessary for topo IIa stimulation. (a) NIH3T3 cells were serum-starved (0.5% serum) for 48 h, followed by microinjection of oncogenic Ras protein (Leu 61; 1 mg/ml; left panels) containing rat IgG as an inert marker. As a control, rat IgG was also injected into cells of a separate plate (panels at the right). Twenty-four h after injection cells were ®xed and stained with ā uorescent antibody against topo IIa protein (top panels), or against the injected rat IgG to identify injected cells (middle panels). For comparison, a phase contrast photograph of the same area is also presented (bottom panels, 6400). (b) Cells transformed by v-ras received injections of anti-Ras antibody Y13-259 (left panels) or the same amount of Rat IgG as control (right panels). Twenty-four h after injection the cells were ®xed and stained with¯uorescent antibodies against topo IIa (upper panels) or against the IgG (lower-panels). As above, injected cells were positive for IgG staining (lower panels). Note that the only topo IIa-positive cell in the anti-ras antibody injected plate failed to receive an injection as indicated by its failure to be stained by the anti immunoglobulin stain 1994). At the same time, the action of the Ras pathway in NIH3T3 cells stimulates cell cycle progression (Stacey and Kung, 1984) . It is possible, therefore, that the oncogenes in this and some other previously reported experiments might induce topo IIa levels as a simple consequence of altering the cell cycle characteristics of the culture. To demonstrate that oncogenic Ras is able to directly stimulate topo IIa levels, independently of its ability to alter cell cycle characteristics, analyses of the topo IIa promoter were performed.
A reporter plasmid consisting of the ®rst 557 bp of the topo IIa promoter linked to a luciferase reporter gene was analysed (Wang et al., 1997; Hochhauser et al., 1992) . The topo IIa reporter plasmid was introduced into NIH3T3 cells by transient transfection together with a plasmid expressing oncogenic ras (and a third plasmid expressing b-galactosidase used for assessment of transfection eciency). When compared with a control plasmid in multiple determinations, the activity of the topo IIa promoter-driven luciferase gene was increased an average of 4.4-fold in cotransfections with a plasmid expressing oncogenic ras (Leu 61 Ras; Figure 3 ). This result was observed in actively proliferating cultures. Stimulation of the topo IIa promoter construct by oncogenic ras increased to near 17-fold in these cells rendered quiescent by serum deprivation following the transfection and prior to luciferase assay ( Figure 3 ). On the other hand, when a plasmid expressing the dominant inhibitory ras mutant, Asn 17, was cotransfected with the topo IIa reporter plasmid, the luciferase activity observed in the treated cultures was inhibited 46% in actively proliferating cultures (10% FCS), and 53% in quiescent cultures (0.5% FCS) compared to cotransfections with control plasmid. Finally, the combination of Leu 61 and Asn 17 ras stimulated the topo IIa controlled-luciferase activity almost as well as Leu 61 ras alone (Figure 3 ). Consistent with this observation, this dominant inhibitory ras mutant has previously been shown to potently inhibit cellular Ras proteins, but to be relatively inactive against oncogenic Ras (Stacey et al., 1991) . These results clearly demonstrate that oncogenic Ras activity can stimulate the topo IIa promoter.
ETS binding site on the topo IIa promoter
Experiments were next designed to determine the transcription factor sites responsible for ras-responsiveness in the topo IIa promoter. The ®rst step was to analyse a series of deletions in the topo IIa promoter to determine the region(s) of the promoter responsible for ras-responsiveness. Seven mutants were analysed ranging in size from the full-length promoter utilized above with 557 bp of promoter sequence, to the minimal promoter containing 32 bp. The basal promoter activity increased with the length of promoter up to 182 bp, after which there was no substantial change in basal promoter activity ( Figure  4a ). This pattern is generally similar to that previously described in another cell line (Wang et al., 1997; Hochhauser et al., 1992) with these same constructs. The response of these deletion constructs to ras-cotransfection was then analysed. Interestingly, there were no major dierences in the extent of stimulation when oncogenic ras was cotransfected with the plasmids containing 32 ± 382 bp of promoter sequence (2.5 ± 4.5-fold stimulation; Figure 4b ). It was only in the full length promoter construct (7557) that a signi®cantly increased level of stimulation by oncogenic ras was observed compared to the minimal promoter ( Figure 4b ). Clearly, a ras-responsive element(s) must be present in the sequence between nucleotide 382 and 557 of the topo IIa promoter. In addition, it appeared that a ras-responsive element(s) was located within the 32 bp of basal promoter sequence, since each of the promoter fragments tested contained this sequence and each was stimulated 2 ± 5-fold by ras activity.
Sequence analyses have identi®ed multiple potential binding sites for various transcriptional factors able to lead to ras-responsiveness within these two promoter regions. The ETS binding site within the full-length promoter element (at position 7480 to 7475) was chosen for further analysis, as proteins of the ETS family have been shown to be involved in the ras-responsiveness of a number of promoters (Hauser et al., 1995) . This site was mutated in the topo IIa promoter to yield plasmid pTIIa-557/ETS mt. There was no signi®cant alteration in the basal promoter activity of the mutant compared to the wild-type topo IIa promoter (data not shown). When Figure 3 Regulation of topo IIa promoter activity by oncogenic ras in NIH3T3 cells. Cells were cotransfected with 2 mg of the full length topo IIa-reporter plasmid (pTIIa-557), together with 2 mg of an empty expression plasmid (pAC-CMV); or the plasmid expressing either Leu 61 ras, or Asn17 ras. Each transfection also included 2 mg of pSV-b-galactosidase as a control. DNA remained in contact with the cells for 18 h after which time the DNA was removed and the cells were cultured either in 10% or 0.5% calf serum (CFS) (as indicated) for an additional 48 h before lysates were prepared and analysed for luciferase and bgalactosidase activity. The graph indicates the fold stimulation of luciferase activity compared to unstimulated controls, and is the mean of 5 ± 7 independent determinations (+s.e.m.). Luciferase activity (with b-galactosidase activity as an internal control for normalization) is presented relative to controls transfections with the empty expression plasmid cotransfected in NIH3T3 cells with the oncogenic rasexpressing plasmid, however, the ras-induced increase in the activity of the mutant promoter (ETSm) was signi®cantly less (P50.05) than was observed with the unaltered pTIIa-557 plasmid (557, Figure 4c ). To con®rm the results with transient transfections, clones of NIH3T3 cells stably expressing either the mutant or the unaltered topo IIa promoter were prepared by cotransfection with a plasmid containing a selectable marker. These cells were then analysed for responsiveness to serum addition (as a means of stimulating endogenous Ras activity). In two separate clones (ETS/C8 and ETS/C9) expressing the mutant topo IIa promoter, serum addition induced a much reduced promoter stimulation than was observed in a clone of NIH3T3 cells (557) transfected with the wild-type promoter construct (Figure 4d ). These results indicate that the Ets like element between nucleotide 382 and 557 of the topo IIa promoter is important for ras-induced topo IIa transactivation.
Ras stimulation of the topo IIa promoter is independent of cell cycle progression
In the above experiments with quiescent cells, ras stimulated the topo IIa promoter by 17-fold. In these cells the oncogenic ras would induce cell cycle progression in addition to any direct stimulation of the topo IIa promoter. The level of stimulation would, therefore, re¯ect a combination of direct stimulation and cell cycle eects of ras. In actively growing cultures, on the other hand, where promoter stimulation was not as great (4.4-fold), the major proportion of the elevated topo IIa promoter activity was most likely due to direct stimulation by Ras activity independent of cell cycle alterations, as the oncogenic ras would not be expected to induce a marked alteration in the overall cell cycle distribution of actively growing transfected cells. To directly con®rm this, advantage was taken of the fact that in each transfection a plasmid expressing b-galactosidase was included as an internal control. Thus, cells were pulsed with labeled thymidine during the last 24 h following transfection, ®xed, stained for b-galactosidase, and ®nally autoradiographed as previously described (Stacey and Kung, 1984) . The proportion of bgalactosidase-containing (positively transfected) cells in the culture which incorporated thymidine was compared to the proportion of thymidine labeled cells transfected with control plasmid. In three individual experiments the cells transfected with oncogenic ras showed only about a 10% increase in the proportion of thymidine labeling compared to cells transfected with control plasmid (60+3% without ras and 66+1% with oncogenic ras co-transfection). The subtle cell cycle alterations induced in proliferating cultures by the transfected oncogenic ras could not have accounted for the 4.4-fold stimulation in topo IIa. In the cycling cells, therefore, the increased activity of the topo IIa promoter induced by ras must have resulted from direct stimulation.
To further con®rm that oncogenic ras is able to induce Topo IIa promoter activity independently of cell cycle eects, experiments were performed in PC12 cells where oncogenic ras induces dierentiation rather than cellular proliferation (Bar-Sagi and Feramisco, 1985; Thomas et al., 1992) . Any eect of oncogenic ras in these cells would, therefore, not result from the induction of cell cycle progression. Although the process of dierentiation in general is known to be associated with¯uctuations of topo IIa protein levels, dierentiation eventually leads to inhibition of cell cycle progression and the decrease of topo IIa levels (Kaufmann et al., 1991) . Transfections similar to those described above were performed in 40 ± 60% con¯uent PC12 cultures. The activity of the topo IIa promoterdriven luciferase gene (pTIIa-557) was increased 11-fold by oncogenic ras, compared to control plasmid ( Figure 5 ). Interestingly, cotransfection with ras Asn17 did not suppress the basal expression of luciferase activity as in the case of NIH3T3 cells. Instead this dominant inhibitory mutant increased the basal reporter activity slightly (near 60%, Figure 5 ) indicating the possibility that cellular Ras in this cell To determine the ability of oncogenic ras to stimulate each of these topo IIa constructs, cotransfections of each was performed with oncogenic ras, and the fold stimulation compared to promoter activity in the absence of ras cotransfection (mean+s.e.m., n=3). (c) The full-length topo IIa promoter (557 nucleotides) with the ETS site at position 480 mutated, was analysed for rasresponsiveness. The fold-stimulation in cotransfections with an oncogenic ras expressing plasmid is reported (mean of four experiments,+s.e.m.) for the mutant promoter (ETSm) and for the wild type promoter (557) (d) NIH3T3 cells were stably transfected with plasmids expressing the luciferase gene controlled either by the ETS mutant or the nonmutated topo IIa promoter. Two clones expressing the mutant (ETS/C8 and ETS/C9) and one expressing the wild type promoter (557) were rendered quiescent by serum deprivation and then stimulated with 10% calf serum for 5 h prior to assay for luciferase activity. The results shown are the mean of three separate experiments (+s.e.m.) line might function negatively in topo IIa regulation, although further study will be required to support this possibility. It is concluded, based upon evidence obtained in these cell lines, that Ras signaling can stimulate topo IIa promoter activity independently of its ability to induce cell cycle progression.
Oncogenic Ras transactivates topo IIa via MEK-ERK pathway
Experiments were next designed to determine the signaling elements downstream of Ras leading to topo IIa promoter stimulation. Raf is known to function downstream of Ras and to stimulate the kinase cascade including MEK and ERK. At the same time, Ras activity is known to stimulate the activity of the stress kinase cascade including SEK and SAPK (Westwick et al., 1994; Lin et al., 1995) . In order to determine which, if either, of these kinase cascades is involved in the signaling pathway leading from Ras to stimulation of topo IIa, inhibitors of these signaling elements were analysed in transient transfection studies. Dominant inhibitory plasmids of Raf (Raf/ KR), SEK (SEK/AL) and MEK (MEK/2A) have previously been characterized and were utilized here. It was ®rst necessary, however, to directly con®rm their activity in these cells. For this purpose plasmids able Figure 3 except that the b-galactosidase and topo IIa reporter plasmid were replaced with one expressing an epitope tagged ERK construct (5 mg of the plasmids pEBG expressing GST-p42 MAPK for ERK). After 48 h the plasmid-expressed ERK protein was isolated from lysates of the transfected cells with immobilized glutathione, and assayed using MBP as the substrate. Kinase assays were quantitated and the relative activity noted. Dominant inhibitory plasmids are RAF/KR for raf, MEK/2A for MEK, and SEK/AL for SEK. (b) The inhibition of SAPK was analysed in analogous co-transfections with GST-p54 SAPK replaced GST-p42MAPK above. The SAPK protein expressed from the transfected plasmids was isolated from the resulting lysates after incubation with glutathione beads and assayed for SAPK using GST-Jun as the substrate. (c) In order to determine the eects of the dominant negative proteins upon topo IIa promoter activity, cells were cotransfected as above but with the b-galactosidase and the topo IIa reporter plasmids replacing the epitope tagged kinase expressing plasmid (used in the kinase assay above). The lysates were assayed for luciferase activity 48 h later, and reported as the fold induction compared to vector control (the mean of 6 ± 8 separate experiments+s.e.m.) to express either the ERK or the SAPK protein tagged with a selectable marker (GST) were transfected into NIH3T3 cells, along with the expression plasmid for a dominant negative upstream gene, and oncogenic ras (or a control). After 48 h the transfected cells were lysed and the tagged kinase proteins isolated and tested for kinase activity using the appropriate substrate.
Oncogenic ras in the absence of inhibitory plasmids was shown to activate both ERK and SAPK, with the former about fourfold more responsive than the latter (Figure 6a,b) . ras-induced ERK activation was inhibited by the dominant negative Raf/KR (about 50%), and completely suppressed by MEK/2A ( Figure  6a ). On the other hand, the dominant inhibitory SEK (SEK/AL) abolished ras-induced SAPK activity (Figure 6b ), while enhancing the activity of ERK (Figure 6a ). The opposite eects of these inhibitory constructs upon ras-induced ERK vs SAPK activation (Figure 6a ,b) might result from crosstalk between these two pathways in NIH3T3 cells. This might be mediated by MKP-1(MAP kinase phosphatase 1), which is induced by stress (Bokemeyer et al., 1996; Liu et al., 1995) , as well as by mitogenic stimuli (Marshall, 1995) , and regulates both ERK (Cook et al., 1997) and SAPK activities (Liu et al., 1995) . Alternatively, since the kinase activity was analysed 48 h after removal of DNA, a ras-induced autocrine mechanisms might also be involved (Gangarosa et al., 1997) . The partial inhibition of ras-induced ERK activity by the inhibitory raf construct, compared to complete inhibition by the inhibitory MEK gene (Figure 6a ) could result from raf-independent signaling from Ras to ERK (Lange-Carter et al., 1993; . In the promoter analyses, MEK/ 2A was found to completely block topo IIa promoter activity stimulated by oncogenic ras (99% inhibition, Figure 6c ). In addition, Raf/KR was also able to eciently inhibit ras-induced promoter activity (Figure  6c ), demonstrating the central role played by the Raf-MEK ± ERK pathway in signaling from Ras to topo IIa. Interestingly, the dominant inhibitory SEK/AL also blocked ras-induced topo IIa promoter activity by approximate 70%. While this indicates the relatively reduced role of SAPK in signaling to topo IIa activity compared to ERK, SAPK is clearly important in stimulation of topo IIa by oncogenic ras.
To con®rm the results with the dominant inhibitory plasmids above, a chemical inhibitor of MEK, PD98059 (Alessi et al., 1995) was employed. This inhibitor (50 mM) was added to cultures following removal of the transfected DNA, and maintained for 48 h until the cells were harvested. As above, the eect of this inhibitor upon stimulation of ERK and SAPK by oncogenic ras was ®rst tested in transfections with the epitope tagged kinase molecules. As expected, the stimulation of ERK by ras was completely blocked in the presence of this inhibitor, together with up to 70% inhibition of the topo IIa promoter activity ( Figure  7a,c) . This treatment, however, was also found to inhibit ras-induced SAPK activation (Figure 7b ). The inhibition of both pathways by this treatment is in contrast to the results with dominant inhibitory constructs, where speci®c inhibition of one kinase resulted in higher levels of the other (Figure 6a,b) . The molecular basis for this dierence is not presently understood, but might indicate a broader range of inhibitory potential of this chemical than observed with dominant negative proteins. Alternatively, this inhibitor may block eects of the autocrine growth factors in this system, which have been previously described to contribute to Ras-and Raf-mediated SAPK activation (McCarthy et al., 1997) . Since PD98059 inhibits both the ERK and SAPK pathways, these results indicate that both these pathways are involved in the induction of topo IIa promoter activity by the action of oncogenic ras.
Both MEK/ERK and SEK/SAPK pathways are involved in topo IIa stimulation
The above studies identify MEK/ERK and SEK/ SAPK as critical elements in signaling from Ras to topo IIa. A series of experiments were next performed to con®rm that both the MEK/ERK and the SEK/ SAPK kinase pathways are required for ecient topo IIa stimulation. To begin with, the activity of both ERK and SAPK were induced together independently of Ras activity to determine if, in the absence of ras, they could induce topo IIa. MEK kinase (MEKK) functions in a parallel signaling pathway to Raf-1 to induce SEK and SAPK activity, and it has also been Figure 6 . After 18 ± 20 h the transfected DNA was removed, and low serum medium (0.5% CFS) was added containing either 50 mM of PD98059 or an equal volume of DMSO for 48 h before collection of the cells and preparation of the lysates. The tagged kinase molecules were then selected and assayed (as in Figure 6 ). (c) To determine the ability of the inhibitor to block activation of the topo IIa promoter, transfections as above were performed except that the b-galactosidase and topo IIa reporter plasmids replaced the epitope tagged kinase plasmids. Luciferase activity is expressed as fold induction over control shown to induce ERK (Lange-Carter et al., 1993; Westwick et al., 1994; Lin et al., 1995) . This kinase thus represents a means of stimulating both ERK and SAPK totally independently of Ras activity. With the tagged kinase molecules described above, it was found that the constitutively active form of MEKK (DMEKK) stimulated both ERK and SAPK actitivity (18; Figure 8a ,b). Unlike the results with oncogenic ras, however, the stimulation of these two kinases by DMEKK was not inhibited by the MEK inhibitor PD98059 (Figure 8a,b) , indicating that Ras and MEKK utilize dierent signaling pathways in activating these two kinases. To directly con®rm the role of ERK and SAPK in topo IIa stimulation, DMEKK was cotransfected with the topo IIa reporter construct. Not only did the DMEKK induce the topo IIa promoter, the inductions were consistently greater than seen even with oncogenic ras (Figure 3 vs 8c) . Finally, the topo IIa stimulation by DMEKK was minimally eected by the inhibitor PD98059 ( Figure  8c ) as expected, since activation of neither ERK nor SAPK by DMEKK was aected by the chemical inhibitor. Thus, studies with DMEKK demonstrate that induction of ERK and SAPK activities by a signaling pathway totally distinct from that utilized by oncogenic Ras strongly induced the topo IIa promoter. The results with the PD98059 inhibitor also support the conclusion that oncogenic Ras induces topo IIa promoter activity as a result of its induction of ERK and SAPK, rather than through an unrelated signaling molecule.
Next, experiments were designed to determine if activation of either MEK/ERK or SEK/SAPK alone was sucient to stimulate topo IIa. A constitutively active MEK construct (MEK/2E) was found to strongly activate ERK (36-fold) without eects on SAPK (Figure 9a ) as previously described . Interestingly, the stimulation of the topoIIa promoter by MEK/2E was only about 30% as eective as stimulation by ras, even though ERK activity itself was stimulated most strongly by MEK/2E (Figures 6a  and 9a,c) . Thus, while ERK appeared to stimulate the topo IIa promoter in the absence of SAPK activity, this stimulation was minimal. To selectively stimulate SAPK activity in the absence of ERK a cell line expressing an IPTG-inducible DMEKK expression plasmid was utilized. Previous studies indicate that in this particular cell line IPTG induced SAPK activity independently of ERK activity . Studies performed here con®rmed that addition of 1 mM of IPTG to the culture for 12 h resulted in a Figure 9 Induction of ERK or SAPK activities alone. (a, c) NIH3T3 Cells were transfected with either the constitutively active MEK expressing plasmid (MEK/2E) or oncogenic Ras (Leu61) for comparison. The eects of these plasmids upon kinase expression or topo IIa promoter activity were determined as in Figure 6 by co-transfections with either tagged MAP kinase expressing plasmids or the topo IIa promoter. Following transfections cells were incubated for 48 h after which plasmid expressed kinase was isolated and assayed (a) or topo IIa promoter activity was determined (c). (b, d) Cells stabily expressing an IPTG-regulated DMEKK gene were grown to 50 ± 70% con¯uence and treated with 1 mM of IPTG (or mock treated) for 12 h prior analysis of the activity of endogenous MAP kinases (b). For these analysis cellular kinases were precipitated with speci®c antibodies and assayed using either MBP or Jun. These same cells were also transfected with the topo IIa promoter construct and cultured 36 h prior to treatment with IPTG for 12 h and analysis of luciferase levels (d) as an indication of topo IIa promoter activity. The data for the promoter assay is the mean of at least three independent experiments (+s.e.m.) Figure 8 Stimulation by DMEKK and its regulation by PD98059. Cells were transfected and treated as detailed in Figure 7 except that the ras expressing plasmid is replaced by the MEKK expressing plasmid pCMV-DMEKK and assayed for SAPK (a), MAPK (b) and the promoter activity (c) sixfold increase of SAPK activity without signi®cant eects on ERK (Figure 9b ). This increase in SAPK activity had no signi®cant eects on the promoter activity of the topo IIa promoter (about 1.3-fold increase) (Figure 9d) . Thus, activation of the SEK/ SAPK pathway alone was not sucient to induce topo IIa stimulation. Further work will be required to determine what eect the activity of another MAP kinase, p38, might have upon topo IIa stimulation. It is clear from these results, however, that neither ERK or SAPK alone is sucient to induce full activity of the topo IIa promoter.
Discussion
The demonstration here that Ras signaling leads to direct topo IIa induction is potentially of far-reaching signi®cance, as it establishes a link between ras, a common tumor mutation, and topoisomerase IIa, a major target of cancer therapeutic treatments. These results indicate that the proliferative signal, which is likely to be constitutively active in tumor cells, has the potential to elevate topo IIa levels. The ras-induced stimulation of topo IIa levels might play a critical role in selectively sensitizing the tumor to the cytotoxic eects of topo II inhibitors. Indeed, this possibility has been recently con®rmed in one preclinical study with human tumor cell lines with or without ras mutations (Koo et al., 1996) , and in our previous study in which the topo II inhibitor etoposide was demonstrated to induce apoptosis in ras-transformed NIH3T3 cells much more eciently than in normal 3T3 cells .
The ®nding that microinjection of oncogenic Ras protein increases topo IIa protein suggests a direct role of Ras activity in topo IIa expression. This was further substantiated by cotransfection analyses in which the topo IIa promoter was induced directly by oncogenic ras. The stimulation was shown to be independent of cell cycle eects as follows: (1) Oncogenic ras induced topo IIa promoter activity in actively proliferating NIH3T3 cells where it was shown that ras had little eect upon cell cycle distribution; (2) Oncogenic ras stimulated topo IIa promoter activity in PC12 cells which do not respond mitogenically to Ras activity; and (3) DMEKK, which has at best weak proliferative properties in NIH3T3 cells , can also strongly induce the topo IIa promoter.
The ability of oncogenic ras to stimulate topo IIa promoter activity suggests that the regulation occurs at the transcriptional level. Mutation of the ETS binding site near the end of the full length topo IIa promoter signi®canly reduced ras-induced topo IIa stimulation, indicating the functional importance of this binding site in ras-mediated transactivation (Hauser et al., 1995) . However, the inhibition of ras-induced transactivation by mutation of the ETS binding site was only partial, implying that additional factors must also be involved. Since many transcriptional factors such as AP-1, ETS, NF-kB and myc are functionally important for ras-induced gene regulation (Hauser et al., 1995) , and since there exists at least one potential binding site for each of these factors in the topo IIa promoter (Wang et al., 1997; Hochhauser et al., 1992) , it will be neccessary to examine more transcription factor binding sites in order to fully understand the detailed mechanisms involved in topo IIa regulation by Ras activity.
The MEK/ERK pathway played a key role in rasinduced topo IIa transactivation. In the presence of oncogenic ras, a dominant negative MEK gene completely inhibited ERK stimulation, while slightly elevating even the stimulated level of SAPK. The fact that this inhibitor completely blocked topo IIa stimulation by ras indicated that the MEK/ERK pathway was essential in ras-induced topo IIa stimulation. This conclusion was con®rmed using the speci®c MEK inhibitor PD98095 (Alessi et al., 1995) . While both means of inhibiting MEK activity eciently blocked the stimulation of the topo IIa promoter by oncogenic ras, only the chemical inhibitor was observed to also block SAPK activity. It is not known why these two means of inhibiting MEK had diering eects upon SAPK, but in each case the importance of MEK in the induction of topo IIa by ras was apparent.
The fact that the SEK dominant negative construct blocked ras-induced SAPK as well as topo IIa induction, albeit less eciently than MEK/2A, suggested that the SEK/SAPK kinase pathway was also involved in topo IIa induction by ras, although its requirement was not as great as with ERK. The requirement for both the MEK/ERK and the SEK/ SAPK kinase pathways in the induction of topo IIa was emphasized by the fact that both had to be stimulated for ecient topo IIa induction. This was made most apparent in cotransfections with the constitutively active DMEKK. In transient transfections this stress controlled kinase induced the activity of both ERK and SAPK independently of Ras activity; and was highly ecient in stimulating topo IIa. On the other hand, a cell line expressing an inducible DMEKK gene responded to DMEKK induction by elevating only SAPK. In this cell line DMEKK induction did not lead to topo IIa induction. Moreover, a constitutively active MEK gene, which induced high levels of ERK activity, was only marginally active in stimulating topo IIa activity. Thus, in all cases the activity of both ERK and SAPK were required for maximal topo IIa stimulation.
It is generally believed that the MEK/ERK pathway is involved in proliferation and oncogenesis, while the SEK/SAPK pathway is involved in stress response, potentially leading to apoptosis (Hunter, 1997) ; although there are some exceptions to this scheme (Irani et al., 1997; Johnson et al., 1996) . Perhaps the most fundamental dierence between normal and tumor cells is the potential for an uncontrolled proliferative signal in the tumor cells. Moreover, stressful enviromental conditions also exist in tumors, such as limited blood supply and increased metabolic activity. Our results indicate that both proliferative signaling and stress signaling in the tumor tissues (Irani et al., 1997) have the potential to contribute to increase of topo IIa expression. This would consequently lead to sensitization of tumors to antitopo IIa treatments.
Materials and methods
Materials
Dulbecco's Modi®ed Eagle Medium (DMEM) and calf serum were obtained from Celox (Hopkins, MN, USA) and Sigma (Sigma, St. Louis, MO, USA), respectively. All other materials for cell culture were supplied by Gibco (Gibco ± BRL, Grand Island, NY, USA). DNA preparation and transfection kits were purchased from Promega. Luciferase was assayed with a kit from Boehringer Mannheim (Indianapolis, IN, USA). b-galactosidase was assayed with a kit from Promega. A rabbit polyclonal antibody to p170 human topoisomerase IIa was purchased from TopoGEN, Inc. (Columbus, OH, USA). An anti-rabbit IgG peroxidase conjugate (POD) was obtained from Boehringer Mannheim (Indianapolis, IN, USA) . Anti-Ras monoclonal antibody was prepared from the hybridoma Y13-259 without further puri®cation as described previously (Smith et al., 1986) . PD 98059 was provided by Alexis cooperation (San Diego, CA, USA). Glutathione agarose beads were from Sigma. Rabbit anti-JNK2 and goat anti-ERK2 polyclonal antibodies were provided by Santa Cruz Biotechnology, Inc. [g-32 P]ATP was from ICN (Costa Mesa, CA, USA). 5-Bromo-2'-deoxyuridine (BrdU) labeling of individual cells was detected using a kit from Boehringer Mannheim GmbH (Mannheim, Germany). Renaissance Western Blot chemiluminescence reagent and re¯ection autoradiography ®lms from DuPont NEN (Boston, MA, USA) were used.
Cell lines
The NIH3T3 cell line and its subclones transformed by oncogenic src, ras and raf were maintained in DMEM medium containing 10% calf serum (CFS) and antibiotics at 378C with 5% CO 2 . The sources and properties of these cells have been previously described (Smith et al., 1986; Chen et al., 1997) . PC12 rat adrenal phaeochromocytoma cells were obtained from ATCC and maintained in DME medium containing 8% heat-inactivated horse serum, 8% heat-inactivated fetal calf serum and antibiotics. Stable transfected NIH3T3 cells expressing DMEKK in response to isopropyl-b-D-thiogalactosidase (IPTG) have been used before for the current experimental conditions .
Microinjections
NIH3T3 cells, and these cells transformed by oncogenic ras (a gift of D Lowy), were cultured in medium containing 10% calf serum. Microinjections were performed into cells within a circular area marked on the back of the coverslip and cultured 24 h prior to ®xation in methanol (7208C) and staining. NIH3T3 cells were cultured in medium containing 0.5% calf serum for 36 h prior to microinjection. Oncogenic ras (Leu61, 1 mg/ml) was combined with non-speci®c rat immunoglobulin (10 mg/ml) for injection; while control injections were of non-speci®c rat immunoglobulin (10 mg/ ml). The non-speci®c rat immunoglobulin also served as control for the neutralizing anti-ras rat monoclonal antibody Y13-259 in ras transformed cells (Mulcahy et al., 1985; Smith et al., 1986; Stacey and Kung, 1984; Stacey et al., 1994) . 200 ± 300 cells were injected on each plate, and several plates were used with each sample for each experiment. These experiments were individually repeated multiple times with results similar to those reported.
Immunostaining and quantitation
Cells on coverslips were washed twice with cold PBS and ®xed in ice-cold absolute ethanol for 20 min at 7208C. Thereafter, cells were incubated with the rabbit antibody which is directed against a peptide speci®c for topoisomerase IIa (TopoGen, Columbus, OH, USA) at a dilution of 1 : 20 in PBS for 45 min, followed by washing and incubation with the second antibody conjugated with Cy3 (1 : 500) for another 45 min. The injected cells were then detected by staining with a¯uoresceine conjugated antibody which speci®cally recognized rat immunoglobulin. For quantitative measurement of the topo IIa signals, cells were further incubated with DAPI solution at 10 mg/ml for 15 min. Coverslips were then mounted in PBS containing 50% glycerol and photographed with a cooled CCD camera (80061000 lines of resolution). Care was taken to ensure that the same areas of the coverslip were photographed under conditions to detect either the topo IIa with CY3 or the injected cells with¯uoresceine. The cells were also photographed under phase contrast optics. The images were exposed and processed identically for cells injected with oncogenic ras, anti-ras and the control immunoglobulin to ensure that their appearance re¯ected true¯uorescence intensity. The total topo IIa signals from 200 ± 300 cells were measured using the Metamorph software. For this purpose the image of the DNA was used to identify the nuclear region of each individual cell. The topo IIa levels within this region were then measured and notated for each cell. Finally, staining for injected immunoglobulin was utilized to positively identify injected cells. The reading for anti-ras and control immunoglobulin-injected cells were analysed statistically.
Plasmids
Cloning of plasmids used in this study was performed in other laboratories. Cloning and characterization of the 5'-anking region of the human Topo IIa gene has been previously described (Hochhauser et al., 1992) . Speci®c regions of the topo IIa promoter were further cloned into a luciferase-expressing vector (PGL2) (Wang et al., 1997) . Topo IIa promoter deletions were created in the upstream sequences of TIIa-557 as previously described (Wang et al., 1997) . pAC-CMV encoding either activated (Leu 61) or dominant negative (Asn-17, N17) Ha-Ras was kindly provided by Dr Christopher B Newgard, University of Texas Southwestern Medical Center. pSV-b-Galactosidase control vector, the positive control plasmid (pGL2-Control) and the negative control vector (pGL2-Basic) were purchased from Promega. pCMV-raf/KR, pCMV-MEKK/KR, pCMV-MEK/2A and pCMV-SEK/AL have been described previously . The plasmids (pEBG) expressing p42MAPK and p54SAPK-GST fusion protein have been used elsewhere . Transformation was performed in DH5a competent cells (Life Technologies). DNA was prepared using EndoFree plasmid Maxi kit from Promega, whereas DNA from promoter constructs of various deletions were extracted using the Mini-prep kit from Boehringer Mannheim.
Deletion and site-directed mutagenesis
Topo IIa promoter deletions were created in the upstream sequences of TIIa-557 as previously described (Wang et al., 1997) . Bases are numbered with respect to the major transcription start point (designated +1). Site-directed mutagenesis was carried out using gene splicing by overlap extension (SOE) (Horton et al., 1993) . Ets-like binding site (TTCCTC) (7480 to 7475) in TIIa557 was changed to GCATCT by three rounds of PCR. A fragment containing the mutated sequence was ®rstly cloned into a pCR2.1 vector by TA cloning method for screening (Introgen) and then inserted into the pGL2 vector via unique KpnI and BglII sites. All the DNA constructs at each step were con®rmed by restriction analysis and/or sequencing.
Transfection and luciferase/b-galactosidase assay
One day after cell seeding in 6-well plates (for NIH3T3 cells at 1. promoter-containing plasmid together with 2 mg L61, or N17 vector, and 2 mg b-galactosidase DNA using the calcium phosphate precipitate method according to the manufacturer's protocol (Promega). After 14 ± 16 h, the DNA containing medium was removed, the culture washed once with PBS, and fresh medium placed on the cultures. In some experiments, the positive and negative control DNA was also included for the transfection to ensure the selectivity of luciferase activity. Cells were lysed 48 h later in 200 ml reporter-lysis buer (Boehringer, Mannheim). The same lysates were used for luciferase reading using a Microlite Luminometer (ML 2250, Dynateck Laboratories, Inc.) and bgalactosidase assay at 420 nM. The luciferase activity was normalized by using b-galactosidase activity as an internal control. The numbers reported re¯ect the relative proportions of luciferase activity compared to the internal control bgalactosidase activity.
Kinase assay
Cells were incubated for 20 min on ice in lysis buer containing 10 mM HEPES, pH 7.4, 1% Triton, 50 mM NaF, 2 mM EDTA, 2 mM Na 3 VO 4 and 0.1% of 2-mecaptoethanol in the presence of appropriate protease inhibitors (1 mM PMSF, 1 mg/ml of aprotonin, leupeptin and pepstatin) (Waskiewicz et al., 1997) . After centrifugation (13 000 g for 10 min at 48C) 500 ml of supernatant was incubated with 30 ml of about 50% glutathione agarose beads for 1 h at 48C. Thereafter, the agarose beads with bound kinases were washed two times in the lysis buer and two times in HEPES binding buer (20 mM HEPES, pH 7.6, 50 mM NaCl, 0.05% Triton X-100, 0.1 mM EDTA and 2.5 mM MgCL 2 ). The ®nal supernatant above the sepharose beads was carefully removed and combined with 35 ml of kinase buer (20 mM HEPES, pH 7.6, 20 mM MgCl 2 , 20 mM ATP, 20 mM b-glycerolphosphate, 20 mM p-nitrophenyl phosphate, 0.5 mM Na 3 VO 4 , 2 mM DTT) and 5 mCi of [g-32 P]ATP. For SAPK and ERK assays, the buer also contained 1.5 mg of the N-terminal 79 amino acids of c-Jun or 5 mg of MBP (myelin basic protein) respectively . The reaction was incubated at 308C for 30 min with occasional agitation. The reaction mixture was then mixed with equal volume of 26SDS ± PAGE sample buer and heated in a boiling water bath for 5 min before loading onto a 12.5% acrylamide gel. The gel was dried and analysed in a phosphoimager.
